|
CA2358061A1
(en)
*
|
2000-09-08 |
2002-03-08 |
Stemcell Technologies Inc. |
Novel antibody compositions for the negative selection of specific rat leukocyte subsets
|
|
DE60235161D1
(de)
*
|
2001-01-25 |
2010-03-11 |
Virxsys Corp |
Methoden und zusammensetzungen zur identifikation von gen-funktion
|
|
US20030121062A1
(en)
*
|
2001-12-21 |
2003-06-26 |
Oxford Biomedica (Uk) Limited |
Transgenic organism
|
|
US20040002158A1
(en)
*
|
2002-06-05 |
2004-01-01 |
Lung-Ji Chang |
Long term expression of lentiviral vectors
|
|
CN1708320A
(zh)
*
|
2002-11-07 |
2005-12-14 |
郎基·常 |
经修饰的树突状细胞
|
|
WO2004069207A2
(en)
*
|
2003-02-04 |
2004-08-19 |
University Of Connecticut Health Center |
Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
|
|
US20040191215A1
(en)
*
|
2003-03-25 |
2004-09-30 |
Michael Froix |
Compositions for induction of a therapeutic response
|
|
US9044381B2
(en)
|
2003-06-24 |
2015-06-02 |
Baxter International Inc. |
Method for delivering drugs to the brain
|
|
US8986736B2
(en)
|
2003-06-24 |
2015-03-24 |
Baxter International Inc. |
Method for delivering particulate drugs to tissues
|
|
AU2004270275B2
(en)
*
|
2003-09-09 |
2010-02-18 |
Virxsys Corporation |
Lentivirus vector-based approaches for generating an immune response to HIV humans
|
|
US20080038824A1
(en)
*
|
2004-01-29 |
2008-02-14 |
National Institute Of Advanced Industrial Science And Technology |
Composition and Method for Elevating Gene Transfer Efficiency
|
|
RU2006144851A
(ru)
|
2004-06-15 |
2008-06-20 |
Бакстер Интернэшнл Инк. (Us) |
Применение терапевтических средств ex-vivo в виде твердых микрочастиц
|
|
CN101072880A
(zh)
*
|
2004-07-01 |
2007-11-14 |
VIRxSYS股份有限公司 |
载体包装细胞系
|
|
CA2577320C
(en)
*
|
2004-09-14 |
2019-08-13 |
Argos Therapeutics, Inc. |
Strain-independent amplification of pathogens and vaccines thereto
|
|
EP2573185A3
(en)
|
2005-02-16 |
2013-06-05 |
Lentigen Corporation |
Lentiviral vectors and their use
|
|
WO2006113622A2
(en)
*
|
2005-04-15 |
2006-10-26 |
University Of Maryland, Baltimore |
Direct vaccination of the bone marrow
|
|
US20080274091A1
(en)
*
|
2005-05-20 |
2008-11-06 |
Virxsys Corporation |
Autologous T Cell Manufacturing Processes
|
|
EP2963118B1
(en)
*
|
2005-06-01 |
2017-08-09 |
California Institute of Technology |
Method of targeted gene delivery using viral vectors
|
|
JP2006345852A
(ja)
*
|
2005-06-16 |
2006-12-28 |
Virxsys Corp |
抗体複合体
|
|
WO2008011636A2
(en)
|
2006-07-21 |
2008-01-24 |
California Institute Of Technology |
Targeted gene delivery for dendritic cell vaccination
|
|
RU2496482C2
(ru)
*
|
2008-03-05 |
2013-10-27 |
Бакстер Интернэшнл Инк. |
Композиции и способы для доставки лекарственных средств
|
|
US9050269B2
(en)
*
|
2009-03-10 |
2015-06-09 |
The Trustees Of The University Of Pennsylvania |
Protection of virus particles from phagocytosis by expression of CD47
|
|
US10952965B2
(en)
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
|
EP2456786B2
(en)
*
|
2009-07-24 |
2017-04-19 |
Immune Design Corp |
Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
|
|
FR2955122B1
(fr)
*
|
2010-01-11 |
2012-09-28 |
Ct Nat De Rech Scientique |
Cellules endotheliales felines organospecifiques et utilisations.
|
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
ES2667425T3
(es)
|
2011-06-10 |
2018-05-10 |
Oregon Health & Science University |
Glucoproteínas y vectores recombinantes de CMV
|
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
|
RU2478711C1
(ru)
*
|
2011-12-19 |
2013-04-10 |
Открытое акционерное общество "Институт стволовых клеток человека" |
Способ повышения эффективности вирусной трансдукции
|
|
EP2794662A1
(en)
*
|
2011-12-22 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
|
AU2013237900B2
(en)
|
2012-03-30 |
2017-07-27 |
Immune Design Corp. |
Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
|
|
US9713635B2
(en)
|
2012-03-30 |
2017-07-25 |
Immune Design Corp. |
Materials and methods for producing improved lentiviral vector particles
|
|
US8323662B1
(en)
|
2012-03-30 |
2012-12-04 |
Immune Design Corp. |
Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
|
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
|
US20140037599A1
(en)
*
|
2012-08-03 |
2014-02-06 |
The Trustees Of The University Of Pennsylvania |
Compositions and Methods of Treating T Cell Deficiency
|
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
US20170218397A1
(en)
*
|
2014-07-30 |
2017-08-03 |
Texas Tech University System |
Conditional cytotoxic gene therapy vector for selectable stem cell modification for anti hiv gene therapy
|
|
CN104610442B
(zh)
*
|
2015-01-30 |
2017-11-24 |
张永辉 |
一种细胞因子颗粒及其应用
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
KR20250134722A
(ko)
*
|
2016-02-12 |
2025-09-11 |
블루버드 바이오, 인코포레이티드. |
Vcn 인핸서 조성물 및 이의 사용 방법
|
|
CN108883136A
(zh)
|
2016-02-12 |
2018-11-23 |
蓝鸟生物公司 |
Vcn增强子组合物及其使用方法
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
KR102673203B1
(ko)
|
2016-04-20 |
2024-06-10 |
센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. |
Pklr의 유전자 발현 증강을 위한 조성물 및 방법
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
US20210139932A1
(en)
*
|
2017-05-03 |
2021-05-13 |
Biomarin Pharmaceutical Inc. |
Improved lentiviruses for transduction of hematopoietic stem cells
|
|
US11597917B2
(en)
|
2017-07-06 |
2023-03-07 |
The Medical College Of Wisconsin, Inc. |
In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
|
|
EP3652296A1
(en)
|
2017-09-20 |
2020-05-20 |
The Charles Stark Draper Laboratory Inc. |
Apparatus for efficient genetic modification of cells
|
|
AU2018352583B2
(en)
|
2017-10-16 |
2025-04-17 |
Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. |
Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency
|
|
JP7557367B2
(ja)
|
2017-11-17 |
2024-09-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細針吸引及び小生検からのtil拡大培養
|
|
WO2019102268A1
(en)
|
2017-11-22 |
2019-05-31 |
Mesoblast International Sarl |
Cellular compositions and methods of treatment i
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US12539316B2
(en)
|
2018-04-11 |
2026-02-03 |
Spacecraft Seven, Llc |
Compositions and methods for stem cell transplant
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US12239693B2
(en)
|
2018-04-27 |
2025-03-04 |
The Medical College Of Wisconsin, Inc. |
Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders
|
|
IL278213B2
(en)
|
2018-04-27 |
2026-04-01 |
Rocket Pharmaceuticals Ltd |
A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
|
|
IL280465B2
(en)
|
2018-07-30 |
2025-03-01 |
Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P |
Methods for gene modification of hematopoietic cells
|
|
JP7614106B2
(ja)
|
2018-10-31 |
2025-01-15 |
メゾブラスト・インターナショナル・エスアーエールエル |
造血幹細胞の拡大
|
|
IL282775B1
(en)
|
2018-11-05 |
2026-05-01 |
Iovance Biotherapeutics Inc |
Selection of enhanced carrier-reactive T cells
|
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
US12453697B2
(en)
|
2018-11-05 |
2025-10-28 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
SG11202109331QA
(en)
|
2019-03-01 |
2021-09-29 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US12565643B2
(en)
|
2019-09-18 |
2026-03-03 |
The Medical College Of Wisconsin, Inc. |
Alpha-galactosidase protein for enzyme replacement therapy (ERT) and methods of use
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
CN115003818A
(zh)
*
|
2020-01-22 |
2022-09-02 |
科济生物医药(上海)有限公司 |
病毒载体转导细胞的方法
|
|
EP4146793A1
(en)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
WO2021226061A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
WO2022032226A1
(en)
|
2020-08-07 |
2022-02-10 |
Spacecraft Seven, Llc |
Plakophilin-2 (pkp2) gene therapy using aav vector
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
CA3195019A1
(en)
|
2020-10-06 |
2022-04-14 |
Maria Fardis |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
JP2024501452A
(ja)
|
2020-12-11 |
2024-01-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
|
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法
|
|
EP4314253A2
(en)
|
2021-03-25 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
US20240269180A1
(en)
|
2021-05-17 |
2024-08-15 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
CA3231018A1
(en)
|
2021-09-09 |
2023-03-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
|
US20230187042A1
(en)
|
2021-10-27 |
2023-06-15 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
JP2025512313A
(ja)
|
2022-04-06 |
2025-04-17 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
EP4522202A1
(en)
|
2022-05-10 |
2025-03-19 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
US20260124242A1
(en)
|
2022-11-04 |
2026-05-07 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
EP4612277A1
(en)
|
2022-11-04 |
2025-09-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
IL328125A
(en)
|
2023-11-06 |
2026-06-01 |
Iovance Biotherapeutics Inc |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
WO2026050217A2
(en)
|
2024-08-27 |
2026-03-05 |
Iovance Biotherapeutics, Inc. |
Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
|